Brandon K. Wilder
YOU?
Author Swipe
View article: Development of novel Aotus nancymaae Non-human primate model for the evaluation of Plasmodium vivax blood stage vaccines and immunoprophylactics
Development of novel Aotus nancymaae Non-human primate model for the evaluation of Plasmodium vivax blood stage vaccines and immunoprophylactics Open
Background Few well-established in vivo animal models reflect the complexity of human malaria infection and immunity, and even fewer have been predictive of the potential of malaria vaccines or prophylactic therapies. Here, we characterize…
View article: Clinical and Pathological Outcomes of Experimental Plasmodium fragile Infection in a Rhesus Macaque
Clinical and Pathological Outcomes of Experimental Plasmodium fragile Infection in a Rhesus Macaque Open
The anatomical and immunological similarities between humans and nonhuman primates (NHPs) make NHPs a viable model for examining Plasmodium spp. infection outcomes. Plasmodium fragile was previously used to model human severe malaria in NH…
View article: A 3D culture model facilitates mass production of in vitro Plasmodium falciparum haemolymph-like sporozoites
A 3D culture model facilitates mass production of in vitro Plasmodium falciparum haemolymph-like sporozoites Open
Implementation of the Alvetex Strata scaffold, optimized medium, and improved ookinete production consistently enables in vitro generation of large quantities of haemolymph-like SPZ.
View article: Identification of cross-stage, cross-species malaria CD8+ T cell antigens
Identification of cross-stage, cross-species malaria CD8+ T cell antigens Open
Malaria is one of the most prevalent parasitic diseases in the world. In 2023, 263 million malaria cases were estimated worldwide. Two species of Plasmodium, P. falciparum and P. vivax, cause most human malaria. Despite the licensing of tw…
View article: HaloPROTAC3 does not trigger the degradation of the halotagged parasitophorous vacuole membrane protein UIS4 during Plasmodium liver stage development
HaloPROTAC3 does not trigger the degradation of the halotagged parasitophorous vacuole membrane protein UIS4 during Plasmodium liver stage development Open
View article: Generation of a Transgenic Plasmodium cynomolgi Parasite Expressing Plasmodium vivax Circumsporozoite Protein for Testing P. vivax CSP-Based Malaria Vaccines in Non-Human Primates
Generation of a Transgenic Plasmodium cynomolgi Parasite Expressing Plasmodium vivax Circumsporozoite Protein for Testing P. vivax CSP-Based Malaria Vaccines in Non-Human Primates Open
Background/Objectives: Malaria, caused by infection with Plasmodium parasites, exacts a heavy toll worldwide. There are two licensed vaccines for malaria as well as two monoclonal antibodies that have shown promising efficacy in field tria…
View article: Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein
Protective antibodies target cryptic epitope unmasked by cleavage of malaria sporozoite protein Open
The most advanced monoclonal antibodies (mAbs) and vaccines against malaria target the central repeat region or closely related sequences within the Plasmodium falciparum circumsporozoite protein (PfCSP). Here, using an antigen-agnostic st…
View article: Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages
Potent AMA1-specific human monoclonal antibody against Plasmodium vivax Pre-erythrocytic and Blood Stages Open
New therapeutics are necessary for preventing Plasmodium vivax malaria due to easy transmissibility and dormancy in the liver that increases the clinical burden due to recurrent relapse. In this manuscript we characterize 12 Pv Apical Memb…
View article: Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5
Natural malaria infection elicits rare but potent neutralizing antibodies to the blood-stage antigen RH5 Open
View article: Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype
Analysis of the diverse antigenic landscape of the malaria protein RH5 identifies a potent vaccine-induced human public antibody clonotype Open
View article: Review 1: "Broadly Inhibitory Antibodies against Severe Malaria Virulence Proteins"
Review 1: "Broadly Inhibitory Antibodies against Severe Malaria Virulence Proteins" Open
The reviewers found the study compelling, providing strong evidence for the existence of broadly inhibitory human antibodies that can recognize and neutralize the diverse range of PfEMP1 variants from Plasmodium falciparum involved in seve…
View article: Reviews of "Broadly Inhibitory Antibodies against Severe Malaria Virulence Proteins"
Reviews of "Broadly Inhibitory Antibodies against Severe Malaria Virulence Proteins" Open
View article: 3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial Performance
3-Position Biaryl Endochin-like Quinolones with Enhanced Antimalarial Performance Open
ELQ-300 is a potent antimalarial drug with activity against blood, liver, and vector stages of the disease. A prodrug, ELQ-331, exhibits reduced crystallinity and improved in vivo efficacy in preclinical testing, and currently, it i…
View article: Evaluation of naturally acquired immune responses against novel pre-erythrocytic Plasmodium vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin
Evaluation of naturally acquired immune responses against novel pre-erythrocytic Plasmodium vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin Open
View article: Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages
Potent AMA1-specific human monoclonal antibody against P. vivax Pre-erythrocytic and Blood Stages Open
New therapeutics are necessary for preventing Plasmodium vivax malaria due to easy transmissibility and dormancy in the liver that increases the clinical burden due to recurrent relapse. We isolated 12 Pv Apical Membrane Antigen 1 (PvAMA1)…
View article: Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine Open
View article: Evaluation of naturally acquired immune responses against novel pre-erythrocytic P. vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin
Evaluation of naturally acquired immune responses against novel pre-erythrocytic P. vivax proteins in a low endemic malaria population located in the Peruvian Amazon Basin Open
Background Plasmodium vivax ( Pv ) represents the most geographically widespread human malaria parasite affecting civilian and military populations in endemic areas. Targeting the pre-erythrocytic (PE) stage of the parasite life cycle is e…
View article: Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype
Analysis of the Diverse Antigenic Landscape of the Malaria Invasion Protein RH5 Identifies a Potent Vaccine-Induced Human Public Antibody Clonotype Open
SUMMARY The highly conserved and essential Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRH5) has emerged as the leading target for vaccines that seek to protect against the disease-causing blood-stage of malaria. However…
View article: Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine Open
Malaria, caused by Plasmodium parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts that have lowered morbidity and mortality. The only P. falciparum vaccine candidates to show field efficacy…
View article: Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine
Accelerated prime-and-trap vaccine regimen in mice using repRNA-based CSP malaria vaccine Open
Malaria, caused by Plasmodium parasites, remains one of the most devastating infectious diseases worldwide, despite control efforts that have lowered morbidity and mortality. The only P. falciparum vaccine candidates to show field efficacy…
View article: The CXCR3 chemokine receptor is critical for the protective immune response to <i>Plasmodium</i> parasite infection of the liver
The CXCR3 chemokine receptor is critical for the protective immune response to <i>Plasmodium</i> parasite infection of the liver Open
No highly efficacious anti-malaria vaccine exists, but whole parasite immunization (WPI) where hosts receive live attenuated Plasmodium parasites that arrest in the liver is the only strategy that confers complete protection against future…
View article: Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver
Creation and preclinical evaluation of genetically attenuated malaria parasites arresting growth late in the liver Open
View article: Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies
Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and may enhance protection of anti-CSP monoclonal antibodies Open
View article: Monoclonal antibodies for malaria prevention
Monoclonal antibodies for malaria prevention Open
View article: Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and enhance protection of anti-CSP monoclonal antibodies
Anti-TRAP/SSP2 monoclonal antibodies can inhibit sporozoite infection and enhance protection of anti-CSP monoclonal antibodies Open
Vaccine-induced sterilizing protection from infection by Plasmodium parasites, the pathogens that cause malaria, will be essential in the fight against malaria as it would prevent both malaria-related disease and transmission. Stopping the…
View article: Malaria vaccine trial shows the potentiating power of incremental progress
Malaria vaccine trial shows the potentiating power of incremental progress Open
View article: Platelet derived growth factor receptor β (PDGFRβ) is a host receptor for the human malaria parasite adhesin TRAP
Platelet derived growth factor receptor β (PDGFRβ) is a host receptor for the human malaria parasite adhesin TRAP Open
View article: Analysis of Pre-Erythrocytic Immunity During Plasmodium Vivax Infection Reveals a Diversity of Responses That is Partially Due to Blood Stage Cross-Reactivity
Analysis of Pre-Erythrocytic Immunity During Plasmodium Vivax Infection Reveals a Diversity of Responses That is Partially Due to Blood Stage Cross-Reactivity Open
BackgroundPlasmodium vivax (Pv) represents the most geographically widespread human malaria parasite. Targeting the pre-erythrocytic (PE) stage of the parasite life cycle is especially appealing for Pv vaccines as it would prevent disease …
View article: Generation of a Genetically Modified Chimeric Plasmodium falciparum Parasite Expressing Plasmodium vivax Circumsporozoite Protein for Malaria Vaccine Development
Generation of a Genetically Modified Chimeric Plasmodium falciparum Parasite Expressing Plasmodium vivax Circumsporozoite Protein for Malaria Vaccine Development Open
Chimeric rodent malaria parasites with the endogenous circumsporozoite protein ( csp ) gene replaced with csp from the human parasites Plasmodium falciparum ( Pf ) and P. vivax ( Pv ) are used in preclinical evaluation of CSP vaccines. Chi…
View article: Platelet Derived Growth Factor Receptor β (PDGFRβ) is a Host Receptor for the human malaria parasite adhesin TRAP
Platelet Derived Growth Factor Receptor β (PDGFRβ) is a Host Receptor for the human malaria parasite adhesin TRAP Open
Following their inoculation by the bite of an infected Anopheles mosquito, the malaria parasite sporozoite forms travel from the bite site in the skin into the bloodstream, which transports them to the liver. The thrombospondin-related ano…